FORTIS MEMORIAL RESEARCH INSTITUTE

Dostarlimab Achieves 100% Remission in Small-Scale Colorectal Cancer Trial

4 months ago

• A groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center reported complete remission in all 18 patients with mismatch repair-deficient colorectal cancer after six months of dostarlimab treatment. • The immunotherapy drug dostarlimab works by blocking PD-1 receptors, enabling the immune system to effectively recognize and destroy cancer cells in patients with specific genetic profiles. • While the results are promising, oncologists emphasize the need for larger trials and longer-term data before confirming the drug's universal effectiveness in treating colorectal cancer.